Pentosan polysulfate: A review of its use in the relief of bladder pain or discomfort in interstitial cystitis

Drugs

Volumn 66, Issue 6, 2006, Pages 821-835

  Anderson, Vanessa R ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Glycosaminoglycan; Interstitial cystitis; Pentosan polysulfate; Pharmacodynamics; Pharmacokinetics; Therapeutic use

Indexed keywords

CYCLOSPORIN A; HEPARIN; HYDROXYZINE; PENTOSAN POLYSULFATE;

ALOPECIA; CLINICAL TRIAL; CYSTALGIA; DIARRHEA; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IN VITRO STUDY; INTERSTITIAL CYSTITIS; LONG TERM CARE; MONOTHERAPY; NAUSEA; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PELVIS PAIN SYNDROME; RECTUM HEMORRHAGE; REVIEW;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; CYSTITIS, INTERSTITIAL; DRUG THERAPY, COMBINATION; HUMANS; PELVIC PAIN; PENTOSAN SULFURIC POLYESTER; TREATMENT OUTCOME;

ANIMALIA;

EID: 33646805791     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666060-00006     Document Type: Review

References (40)

1. Kahn BS, Stanford EJ, Mishell DR, et al. Management of patients with interstitial cystitis or chronic pelvic pain of bladder origin: a consensus report. Current Medical Research & Opinion 2005; 21 (4): 509-16
2. Parsons CL. Evidence-based strategies for recognizing and managing IC. Contemp Urol 2003 Feb; 15 (2): 22-35
3. Curhan GC, Speizer FE, Hunter DJ, et al. Epidemiology of interstitial cystitis: a population based study. J Urol 1999 Feb; 161 (2): 549-52
4. Butrick CW. Interstitial cystitis and chronic pelvic pain: new insights in neuropathology, diagnosis, and treatment. Clinical Obstetrics & Gynecology 2003; 46 (4): 811-23
5. Chancellor MB, Yoshimura N. Treatment of interstitial cystitis. Urology 2004 Mar; 63 (3 Suppl 1): 85-92
6. Evans RJ. Treatment approaches for interstitial cystitis: multimodality therapy. Reviews in Urology 2002; 4 Suppl. 1: S16-20
7. Ortho-McNeil Pharmaceutical I. Elmiron® 100 mg (pentosan polysulfate sodium) capsules [online]. Available from URL: http://www.orthoelmiron.com [Accessed 2006 Jan 5]
8. Parsons CL. The therapeutic role of sulfated polysaccharides in the urinary bladder. Urol Clin North Am 1994 Feb; 21 (1): 93-100
9. Kalota SJ, Stein PC, Parsons CL. Prevention of acrolein-induced bladder injury by pentosanpolysulfate. J Urol 1992 Jul; 148 (1): 163-6
10. Parsons CL, Forrest J, Nickel JC, et al. Effect of pentosan polysulfate therapy on intravesical potassium sensitivity. Urology 2002 Mar; 59 (3): 329-33
11. Russell AL. Glycoaminoglycan (GAG) deficiency in protective barrier as an underlying, primary cause of ulcerative colitis, Crohn's disease interstitial cystitis and possibly Reiter's syndrome. Med Hypotheses 1999 Apr; 52 (4): 297-301
12. Sadhukhan PC, Tchetgen M-B, Rackley RR, et al. Sodium pentosan polysulfate reduces urothelial responses to inflammatory stimuli via an indirect mechanism. J Urol 2002 Jul; 168 (1): 289-92
13. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997 Apr; 336 (15): 1066-71
14. Chiang G, Patra P, Letourneau R, et al. Pentosanpolysulfate inhibits mast cell histamine secretion and intracellular calcium ion levels: an alternative explanation of its beneficial effect in interstitial cystitis. J Urol 2000 Dec; 164 (6): 2119-25
15. Chiang G, Patra P, Letourneau R, et al. Pentosanpolysulfate (Elmiron) is a potent inhibitor of mast cell histamine secretion. Adv Exp Med Biol 2003; 539 (Pt B): 713-29
16. National Toxicology Program Public Health Services, National Institutes of Health, US Department of Health and Human Services. NTP technical report on the toxicology and carcinogenesis studies of Elmiron (Cas No. 37319-17-8) in F344/N rats and B6C3F1 mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser 2004 May; 512: 7-289
17. Zaslau S, Riggs DR, Jackson BJ, et al. In vitro effects of pentosan polysulfate against malignant breast cells. Am J Surg 2004 Nov; 188 (5): 589-92
18. 3H]pentosan polysulfate sodium (PPS) in healthy human volunteers. Xenobiotica 2005 Aug; 35 (8): 775-84
19. Faaij RA, Srivastava N, van Griensven JMT, et al. The oral bioavailability of pentosan polysulphate sodium in healthy volunteers. Eur J Clin Pharmacol 1999 Feb; 54 (12): 929-35
20. Modi NB, Kell S, Simon M, et al. Pharmacokinetics and pharmacodynamics of warfarin when coadministered with pentosan polysulfate sodium. J Clin Pharmacol 2005 Aug; 45 (8): 919-26
21. Nyska A, Nold JB, Johnson JD, et al. Lysosomal-storage disorder induced by elmiron following 90-days gavage administration in rats and mice. Toxicol Pathol 2002; 30 (2): 178-87
22. Mulholland SG, Hanno P, Parsons CL, et al. Pentosan polysulfate sodium for therapy of interstitial cystitis: a double-blind placebo-controlled clinical study. Urology 1990 Jun; 35 (6): 552-8
23. Parsons CL, Benson G, Childs SJ, et al. A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosanpolysulfate. J Urol 1993 Sep; 150 (3): 845-8
24. Sant GR, Propert KJ, Hanno PM, et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol 2003 Sep; 170 (3): 810-5
25. Sairanen J, Tammela TL, Leppilahti M, et al. Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol 2005 Dec; 174 (6): 2235-8
26. Hanno PM. Analysis of long-term Elmiron therapy for interstitial cystitis. Urology 1997 May; 49 (Suppl. 5A): 93-9
27. Jepsen JV, Sall M, Rhodes PR, et al. Long-term experience with pentosanpolysulfate in interstitial cystitis. Urology 1998 Mar; 51 (3): 381-7
28. van Ophoven A, Heinecke A, Hertle L. Safety and efficacy of concurrent application of oral pentosan polysulfate and subcutaneous low-dose heparin for patients with interstitial cystitis. Urology 2005 Oct; 66 (4): 707-11
29. Nickel JC, Barkin J, Forrest J, et al. Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology 2005 Apr; 65 (4): 654-8
30. Waters MG, Suleskey JF, Finkelstein LJ, et al. Interstitial cystitis: a retrospective analysis of treatment with pentosan polysulfate and follow-up patient survey. J Am Osteopath Assoc 2000 Mar; 100 (3 Suppl): S13-18
31. Rice L, Kennedy D, Veach A. Pentosan induced cerebral sagittal sinus thrombosis: a variant of heparin induced thrombocytopenia. J Urol 1998 Dec; 160 (6 Pt 1): 2148
32. Gill S, Naiman SC, Jamal A, et al. Massive bleeding on a bladder protectant: a case report of pentosan polysulfate sodium-induced coagulopathy. Arch Intern Med 2002 Jul 22; 162 (14): 1644-5
33. Tardy-Poncet B, Tardy B, Grelac F, et al. Pentosan polysulfate-induced thrombocytopenia and thrombosis. Am J Hematol 1994; 45 (3): 252-7
34. Siddiqui MN, Ranasinghe JS, Siddiqui S. Epidural hematoma after epidural steroid injection: a possible association with use of pentosan polysulfate sodium [letter]. Anesthesiology 2001 Nov; 95 (5): 1307
35. Wu EQ, Birnbaum H, Mareva M, et al. Interstitial cystitis: cost, treatment and co-morbidities in an employed population. Pharmacoeconomics 2006; 24 (1): 55-65
36. Parsons CL, Dell J, Stanford EJ, et al. Increased prevalence of interstitial cystitis: previously unrecognized urologic and gynecologic cases identified using a new symptom questionnaire and intravesical potassium sensitivity. Urology 2002 Oct; 60 (4): 573-8
37. Selo-Ojeme DO, Onwude JL. Interstitial cystitis. J Obstet Gynaecol 2004 Apr; 24 (3): 216-25
38. Nickel JC. Interstitial cystitis: a chronic pelvic pain syndrome. Med Clin North Am 2004; 88 (2): 467-81
39. Dell JR, Parsons CL. Multimodal therapy for interstitial cystitis. J Reprod Med 2004 Mar; 49 (3 Suppl.): 243-52
40. Parsons CL. Prostatitis, interstitial cystitis, chronic pelvic pain, and urethral syndrome share a common pathophysiology: lower urinary dysfunctional epithelium and potassium recycling. Urology 2003; 62 (6): 976-82